Lenvatinib
| CAS No. | 417716-92-8 |
|---|---|
| MDL No. | MFCD16038644 |
| MF | C21H19ClN4O4 |
| MW | 426.90 |
| InChI Key | WOSKHXYHFSIKNG-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Lenvatinib is a quinoline derivative, specifically the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. It is a multi-kinase inhibitor and orphan drug used as its mesylate salt in the treatment of thyroid cancers resistant to radioiodine. It functions as a vascular endothelial growth factor receptor antagonist, an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, and a fibroblast growth factor receptor antagonist. It belongs to quinolines, aromatic ethers, monocarboxylic acid amides, aromatic amides, monochlorobenzenes, cyclopropanes, and phenylureas. It is the conjugate base of lenvatinib(1+).
| CAS No. | 417716-92-8 |
|---|---|
| Product Name | Lenvatinib |
Biological Targets
FLT1·FLT4·KDR
Associated Conditions
melanoma·intrahepatic cholangiocarcinoma·cancer·Central Nervous System Neoplasm·neuroendocrine carcinoma·
* The information provided here is compiled from public sources and is for reference only.
